CHF5074

Research use only, not for human use.

CHF5074, a γ-secretase modulator, reduces Aβ42/40 secretion (IC50: 3.6/18.4 μM).

CHF-5074, also known as CSP-1103, is a γ-secretase modulator. CHF-5074 reduces Aβ42 and Aβ40 secretion, with an IC50 of 3.6 and 18.4 μM respectively. CHF5074 reduces brain beta-Amyloid pathology in a transgenic mouse model of Alzheimer's Disease without causing peripheral toxicity. CHF5074 is a non-steroidal anti-inflammatory derivative holding disease-modifying potential for the treatment of Alzheimer's disease.

——

Animal Model:Male and female Tg2576 transgenic mice expressing Swedish mutated form of human APP (APPswe)Dosage:375 ppm Administration:Oral administration; 375 ppm in the diet for 17 weeks Result:Reduced total brain Aβ42 and Aβ40 levels, and brain plaque burden in aged Tg2576 mice. Caused no COX-mediated toxic effects in the gastrointestinal tract and Notch-mediated cell differentiation abnormalities in the ileum.

CHF-5074 | CHF5074 | CHF 5074 | CSP-1103

Angiogenesis

EGFR

Beta Amyloid| γ secretase

Neurological Disease

——

749269-83-8

325.16

C16H11Cl2FO2

>98% (HPLC)

DMSO : ≥ 37 mg/mL; 113.79 mM

Clc1cc(c2c(F)cc(C3(CC3)C(=O)O)cc2)ccc1Cl

1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years